A 65-year-old man with hypertension and hyperlipidemia presents for a routine evaluation. He has no history of cardiovascular disease. Based on risk calculators, his annual risk of stroke is 4%. A randomized controlled trial of a new antiplatelet agent showed that over one year, the treated group had a 2% stroke incidence compared to 4% in the placebo group. However, the treated group had a 1.5% incidence of major bleeding events compared to 0.5% in the placebo group. Which of the following statements best reflects the clinical significance of this therapy’s risk–benefit profile?